Have any FDA public records or Freedom of Information Act releases named Dr. Paul Cox in Neurocept filings?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Available reporting and public documents in the supplied search results do not show any FDA public records or FOIA releases that specifically name “Dr. Paul Cox” in filings for a company called Neurocept; the sources that mention Paul Cox focus on his L‑serine work and press coverage of his research [1] [2] [3]. FDA pages and summaries in the results are general or about other drugs and approval timelines; none of the provided FDA materials or news pieces tie Cox to Neurocept or to FDA FOIA documents in Neurocept filings [4] [5] [6].
1. What the available sources say about Paul Cox and L‑serine
Longform and feature articles describe Paul Alan Cox as an ethnobotanist who has promoted L‑serine as a potential neuroprotective therapy and who carried data to the FDA to start clinical trials; Fortune’s profile and a Good News Network story both chronicle Cox’s work and advocacy around L‑serine and trials, but they are journalistic profiles rather than FDA docket listings [1] [2]. Wikipedia’s biographical entry summarizes his career and public profile but does not document FDA filings that name him in corporate submissions [3].
2. What the supplied FDA and regulatory records cover (and do not cover)
The search results include FDA landing pages, press announcements and downloadable FDA materials that describe agency responsibilities and specific drug approval activities, plus reporting on FDA calendars and PDUFA dates [4] [5] [6]. None of those documents in the provided set explicitly reference Neurocept or identify Dr. Paul Cox by name in the context of a company filing or FOIA release [4] [5] [6].
3. On Neurocept: available sources do not mention the company in filings
The results contain no material that connects a company named Neurocept to FDA submissions or FOIA releases in this collection. There is no Neurocept docket, press release, or regulatory summary in the provided items, so any statement that FDA records name Cox in Neurocept filings is not supported by the supplied reporting (not found in current reporting).
4. How to interpret the absence of evidence in this dataset
An absence of matched references in this limited set of search results does not prove such records do not exist anywhere. It does mean that among the specific sources you provided, reporting focuses on Cox’s L‑serine research and FDA-wide activity, not on Neurocept filings or FOIA documents naming him [1] [2] [4]. For a definitive answer one must search FDA FOIA logs, FDA FOIA reading rooms, or Neurocept’s public SEC/press filings—none of which appear among the supplied materials [4].
5. Competing perspectives and potential agendas in the sources
Profiles in popular outlets (Fortune, Good News Network) present Cox’s work with a positive, sometimes promotional tone emphasizing potential breakthroughs and his outsider scientist narrative [1] [2]. Those pieces can create public expectations and may understate the distinction between initiating clinical trials and formal company NDA/BLA filings. The FDA and science-trade reporting included here (FDA pages, Nature Reviews and other outlets) emphasize procedural timelines, agency roles and the complexity of approvals rather than advocacy for individual researchers [4] [6].
6. Recommended next steps to confirm whether Cox appears in Neurocept FOIA or FDA records
To resolve this precisely, consult: (a) the FDA FOIA reading room and FOIA request logs for any releases referencing “Paul Cox” or “Neurocept”; (b) the FDA Dockets and Drugs@FDA database for Neurocept submissions; and (c) Neurocept corporate filings and press releases. Those targeted searches are not present in the supplied results, so I cannot cite them here (not found in current reporting).
Limitations: This analysis is restricted to the documents and excerpts you provided; none explicitly names Dr. Paul Cox in Neurocept filings or FOIA releases [1] [2] [4] [5] [3] [6].